6533b7dbfe1ef96bd1270ba0

RESEARCH PRODUCT

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

B SposatoM ScaleseM MilaneseS MasieriC CavaliereM LatorreN ScichiloneA RicciA CrestiP SantusC OlivieriA PerrellaP RoglianiP PaggiaroB SposatoM. G MiglioriniM Di TomassiC OlivieriA PerrellaG CamiciottoliR MaselliG PelaiaM. T BuscetiE SabatoM. G CagnazzoF ColomboL PalumboA RavazziC BuccaM. F CaiaffaA BerraC CalabreseA. A StanziolaP SchinoM Di GioacchinoP RoglianiM CazzolaA SegretiE. A PastorelloG ScibiliaA VianelloM. R MarchiL PaladiniS BaglioniM AbbrittiF AlmerigognaA MatucciA VultaggioE MaggiP MaestrelliG GuarnieriG SteinhilberM BonaviaP RottoliE BargagliG SennaM CaminatiL MacchiaV BelliaN ScichiloneP PaggiaroF NovelliM LatorreL VerguraS MasieriM ScaleseY RosatiM MilaneseI FollettiR PioA PioU MaccariC MaggiorelliR ScalaL VignaleN PuleràG. E CarpagnanoM. P Foschino Barbaro The Omalizumab Italian Study Group

subject

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaTreatment outcomeMEDLINEOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin Eeosinophil Omalizumab anti-IgE asthmaLeukocyte CountText miningForced Expiratory VolumeInternal medicineEosinophiliamedicineHumansImmunology and AllergyAnti-Asthmatic AgentsBlood eosinophilAgedRetrospective StudiesAsthmabiologybusiness.industryRetrospective cohort studyMiddle AgedasthmaPrognosismedicine.diseaseEosinophilsTreatment Outcomeinflammationbiology.proteinFemalebusinessmedicine.drug
yearjournalcountryeditionlanguage
2019-01-01
10.1016/j.jaip.2019.03.006https://hdl.handle.net/11588/758945